Reye syndrome labeling
This article was originally published in The Tan Sheet
Executive Summary
"OTC feedback" meeting scheduled between FDA and the Aspirin Foundation of America on April 5 to address the labeling of all oral and rectal aspirin products and non-aspirin salicylates. In recent comments to the agency, AFA opposed an FDA proposal to require a Reye syndrome warning on all aspirin and non-aspirin salicylates ("The Tan Sheet" Jan. 10, p. 3)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning